Table 3.

Hazards of Val174Ala and SLCO1B1 gene risk score to 20-year intolerance-free survival in individuals on higher equivalent doses (≥40 mg)

	Val174Ala (CC vs. CT + TT): HR (95% CI) P-value	LR test (clinical model + Val174Ala) χ² (df) P-value	SLCO1B1 GRS (high- vs. low-risk): HR (95% CI) P-value	LR test (clinical model + SLCO1B1 GRS) χ² (df) P-value
GSI (n = 2454)	2.49 (1.09–5.68) P = 0.03	χ² (1) = 3.05 P = 0.08	2.44 (1.46–4.08) P < 0.001	χ² (1) = 9.1481 P = 0.0025
SRM (n = 2402)	3.01 (1.31–6.94) P = 0.01	χ² (1) = 5.18 P = 0.023	2.51 (1.38–4.58) P = 0.003	χ² (1) = 8.96 P = 0.002
SRSR (n = 2347)	2.64 (0.63–11.1) P = 0.2	χ² (1) = 1.40 P = 0.24	2.89 (1.17–7.14) P = 0.02	χ² (1) = 5.35 P = 0.020

All models adjusted for age, gender, previous cardiovascular events, statin type, and statin dose.

CI, confidence interval; GRS, gene risk score; GSI, general statin intolerance; HR, hazard ratios; LR test, likelihood ratio test; SRS, statin-related myopathy; SRSR, statin-related suspected rhabdomyolysis. Bold values denote statistical significance at P < 0.05 threshold.